Actively Recruiting
Phase 2 Evaluation of Oral PI3K Inhibitor RLY-2608 in Adults and Children with PIK3CA Related Overgrowth Spectrum and Malformations
Led by Relay Therapeutics, Inc. · Updated on 2026-08-25
277
Participants Needed
40
Research Sites
13 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying the safety and effects of a mutant-selective drug called RLY-2608, which targets the PI3K protein, in adults and children with PIK3CA Related Overgrowth Spectrum PROS and malformations caused by PIK3CA mutations. This Phase 2 study is divided into three parts dose selection, exploration of different participant groups, and a randomized, double-blinded comparison against placebo. The study aims to understand how this drug works in these rare conditions involving abnormal tissue growth. Participants will receive oral doses of RLY-2608 across different age groups, including adults and children as young as 2 years old. The study includes dose escalation for younger children and dose expansion cohorts for various subpopulations. The final part randomizes participants aged 6 years and older to receive either RLY-2608 or a placebo. Dosing schedules and groups are tailored by age and condition, with careful monitoring throughout. During the trial, participants will provide tissue or fluid samples to assess PIK3CA mutations. Researchers will track side effects, safety labs, vital signs, and heart function regularly during treatment cycles. They will measure changes in lesion size and response rates at baseline and various points up to 24 weeks, with additional long-term follow-up for response duration and drug levels in the blood. Quality of life and symptom improvements will also be evaluated monthly during treatment. The study continues until 2031, with ongoing safety and efficacy assessments.
CONDITIONS
Brief Title
A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation (The ReInspire Study)
Research Team
R
Relay Therapeutics, Inc
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here